Verseon bets physics can take drug design beyond AI’s training data

Summary

Verseon, a Bay Area pharma company, uses a computational platform launched in 2002 to design small-molecule drugs, positioning its physics-based approach as an alternative to AI-driven drug discovery methods used by competitors like Recursion and Exscientia.